This database contains 123 studies, archived under the term: "cholinesterase inhibitors"
Click here to filter this large number of results.
Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study
Mild cognitive impairment (MCI) in Parkinson’s disease (PD) may be associated with subtle functional impairment and worse quality of life. The objective of this study was to determine the efficacy and tolerability of rivastigmine for PD-MCI. Patients with PD-MCI (n = 28) were enrolled in a 24-week, randomized, double-blind, placebo-controlled, crossover, single-site study of the rivastigmine transdermal […]
Longitudinal medication usage in Alzheimer disease patients
Zhu, Carolyn W.,
Livote, Elayne E.,
Kahle-Wrobleski, Kristin,
Scarmeas, Nikolaos,
Albert, Marilyn,
Brandt, Jason,
Blacker, Deborah,
Sano, Mary,
Stern, Yaakov
This study examined in detail patterns of cholinesterase inhibitors (ChEIs) and memantine use and explored the relationship between patient characteristics and such use. Patients with probable Alzheimer disease AD (n=201) were recruited from the Predictors Study in 3 academic AD centers and followed from early disease stages for up to 6 years. Random effects logistic […]
Treatment effects of therapeutic cholinesterase inhibitors on visuospatial processing in Alzheimer’s disease: A longitudinal functional MRI study
Thiyagesh, Subha N.,
Farrow, Tom F. D.,
Parks, Randolph W.,
Accosta-Mesa, Hector,
Hunter, Michael D.,
Young, Claire,
Wilkinson, lain D.,
Woodruff, Peter W. R.
Background/Aims: Visuospatial impairments are known to occur in Alzheimer’s disease (AD). We hypothesised that functional magnetic resonance imaging (fMRI) response in task-related brain regions would be impaired in patients with AD during the task and that treatment with acetyl cholinesterase inhibitors would enhance activations in brain regions concerned with this visual perceptual processing. Method: Ten […]
No effect of donepezil on striatal dopamine release in mild to moderate Alzheimer’s disease
Objective: Work in experimental animals suggests that an interaction with dopaminergic networks might explain some of the therapeutic effects of the cholinesterase inhibitor class of drugs. This study aimed to test whether acute (single 5 mg) or 4–8 weeks (5–10 mg) of treatment with oral donepezil would elicit measurable striatal dopamine (DA) release in patients […]
A serum protein-based algorithm for the detection of Alzheimer disease
O'Bryant, Sid E.,
Xiao, Guanghua,
Barber, Robert,
Reisch, Joan,
Doody, Rachelle,
Fairchild, Thomas,
Adams, Perrie,
Waring, Steven,
Diaz-Arrastia, Ramon
Objective: To develop an algorithm that separates patients with Alzheimer disease (AD) from controls. Design: Longitudinal case-control study. Setting: The Texas Alzheimer’s Research Consortium project. Patients: We analyzed serum protein-based multiplex biomarker data from 197 patients diagnosed with AD and 203 controls. Main Outcome Measure: The total sample was randomized equally into training and test […]
Achetylcholinesterase (AChE) inhibition and serum lipokines in Alzheimer’s disease: friend or foe?
Kovacs, Janos,
Pákáski, Magdolna,
Juhasz, Anna,
Feher, Agnes,
Drótos, Gergely,
Fazekas, Csilla Orsike,
Horvath, Tamas Laszlo,
Janka, Zoltan,
Kálmán, János
Throughout the natural progression of Alzheimer’s disease (AD), the body mass index (BMI) decreases. This is believed to be brought on by the disturbance in the central lipid metabolism, but the exact mechanism is yet unknown. Adipokines (adiponectin, leptin), hormones produced by the adipose tissue, change glucose and lipid metabolism, and have an anorectic effect […]
Greater responsiveness to donepezil in Alzheimer patients with higher levels of acetylcholinesterase based on attention task scores and a donepezil PET study
Kasuya, Masashi,
Meguro, Kenichi,
Okamura, Nobuyuki,
Funaki, Yoshihito,
Ishikawa, Hiroyasu,
Tanaka, Naofumi,
Iwata, Ren,
Yanai, Kazuhiko
The aim of the study was to predict donepezil responders among patients with Alzheimer disease (AD) based on cognitive tests and positron emission tomography. The Mini-Mental State Examination, Digit Symbol subtest (DigSm) of Wechsler Adult Intelligence Scale Revised, and Trail-Making Test A were administered for 80 patients with AD to assess global function, attention, and […]
Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial
Objective: Because cholinergic deficits are prominent in dementia with Lewy bodies (DLB), we investigated the effects of a cholinesterase inhibitor, donepezil, in such patients in a randomized, double-blind, placebo-controlled exploratory phase 2 trial.; Methods: One-hundred forty patients with DLB, recruited from 48 specialty centers in Japan, were randomly assigned to receive placebo or 3, 5, […]
Longitudinal changes of fractional anisotropy in Alzheimer’s disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study
Likitjaroen, Y.,
Meindl, T.,
Friese, U.,
Wagner, M.,
Buerger, K.,
Hampel, H.,
Teipel, S. J.
Diffusion tensor imaging (DTI) demonstrates decline of fractional anisotropy (FA) as a marker of fiber tract integrity in Alzheimer’s disease (AD). We aimed to assess the longitudinal course of white matter microstructural changes in AD and healthy elderly control (HC) subjects and to evaluate the effects of treatment with the cholinesterase inhibitor galantamine on white […]